ArticleFrontiers in pharmacology2022
Serum Homocysteine Level Predictive Capability for Severity of Restenosis Post Percutaneous Coronary Intervention.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- A systematic review and bioinformatic study on clinical, paraclinical, and genetic factors predisposing to stent restenosis following percutaneous coronary intervention.BMC cardiovascular disorders · 2024Pooled it
- Predicting carotid in-stent restenosis with dual-energy CT: a multicenter study.European radiology · 2026Article
- Changes of Serum CTRP12 in Patients With Coronary Artery Disease After the Treatment of Percutaneous Coronary Intervention and Its Relationship With In-Stent Restenosis.Clinical cardiology · 2026Article
- Comprehensive Analysis in the Nutritional Composition, Bioactive Contents, and Antioxidant Capacity of Walnut (Foods (Basel, Switzerland) · 2025Article
- Mutual mediation effects of homocysteine and PCSK9 on coronary lesion severity in patients with acute coronary syndrome: interplay with inflammatory and lipid markers.Lipids in health and disease · 2025Article
- Yiqi Huoxue Tongluo decoction combined with conventional medicine therapy: effects on restenosis rates and clinical efficacy in patients with coronary heart disease undergoing percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2025Article
- Precision prediction of hyperhomocysteinemia development in perimenopausal women using LASSO regression.Frontiers in reproductive health · 2025Article
- Predicting long-term prognosis after percutaneous coronary intervention in patients with acute coronary syndromes: a prospective nested case-control analysis for county-level health services.Frontiers in cardiovascular medicine · 2023Article
- Editorial: Vascular smooth muscle cell fate and vascular remodeling: Mechanisms, therapeutic targets, and drugs, volume I.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.